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The genetic basis of many common human diseases is expected to be highly heterogeneous, with multiple causative
loci and multiple alleles at some of the causative loci. Analyzing the association of disease with one genetic marker
at a time can have weak power, because of relatively small genetic effects and the need to correct for multiple
testing. Testing the simultaneous effects of multiple markers by multivariate statistics might improve power, but
they too will not be very powerful when there are many markers, because of the many degrees of freedom. To
overcome some of the limitations of current statistical methods for case-control studies of candidate genes, we
develop a new class of nonparametric statistics that can simultaneously test the association of multiple markers
with disease, with only a single degree of freedom. Our approach, which is based on U-statistics, first measures a
score over all markers for pairs of subjects and then compares the averages of these scores between cases and
controls. Genetic scoring for a pair of subjects is measured by a “kernel” function, which we allow to be fairly
general. However, we provide guidelines on how to choose a kernel for different types of genetic effects. Our global
statistic has the advantage of having only one degree of freedom and achieves its greatest power advantage when
the contrasts of average genotype scores between cases and controls are in the same direction across multiple
markers. Simulations illustrate that our proposed methods have the anticipated type I–error rate and that they can
be more powerful than standard methods. Application of our methods to a study of candidate genes for prostate
cancer illustrates their potential merits, and offers guidelines for interpretation.
Introduction
The genetic basis of common human diseases is widely
studied by evaluating the association of genetic variants
with disease status, as in candidate-gene case-control
studies. The power of this approach depends on the ef-
fect size of the disease locus (typically considered in
terms of an odds ratio), the frequency of the disease
allele(s), the frequency of the marker allele(s), and the
magnitude of linkage disequilibrium between the marker
and disease loci (Zondervan and Cardon 2004). Al-
though there is debate on whether common diseases are
caused by many rare mutations (Pritchard and Cox
2002) or a few common genetic variants (Reich and
Lander 2001), it is clear that allelic heterogeneity will
dilute power to detect genetic associations (Slager et al.
2000). Furthermore, when multiple genes are function-
ally related—for instance, when their products are re-
lated through a cascade of enzymatic reactions—mu-
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tations at any of several genes could lead to disease. Also,
it may not be unusual for genes in a functional pathway
to have complex interactions, given evidence of feedback
loops and compensatory enzymatic activities among the
protein products of biosynthesis pathways.
Standard methods to evaluate the association of mul-
tiple markers with disease status are based on either
single-marker analyses or multimarker multivariate
analyses. For single-marker analyses of diallelic mark-
ers, it is common to compare the allele frequencies of
each marker between cases and controls by use of Ar-
mitage’s test for trend (Sasieni 1997) and to adjust for
multiple testing by use of either the Bonferroni correc-
tion or a permutation P value for the most extreme
statistic. This approach is likely to be most powerful if
there is only a single marker strongly associated with
disease. For multimarker multivariate analyses, one can
use logistic regression to test simultaneously the main
effects (and possibly interactions) of multiple markers.
For each marker, a covariate can be created, such as the
number of rare alleles at each marker. When this type
of coding is used in logistic regression, the resulting
score statistic for each marker is Armitage’s test for
trend, so simultaneously testing multiple marker loci by
this type of coding and using the score statistic from
logistic regression is a multivariate version of Armitage’s
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score statistic. For K markers, each coded into covari-
ates, the resulting score statistic has a x2 distribution
with K degrees of freedom. This statistic is equivalent
to the multivariate Hotelling’s statistic proposed by2T
Fan and Knapp (2003). Although this approach can be
more powerful than testing each marker separately
(Longmate 2001), it still suffers from weak power be-
cause of the large number of degrees of freedom. When
evaluating the association of multiple genes with disease
status, the power to detect associations can be weak
when the effects of individual genes are weak and when
correcting for multiple testing.
An alternative approach to evaluate the association
of multiple genes with disease status might be to model
all the complex interrelationships of genes, say within
a common pathway, and how they relate to disease.
This parametric method, however, would lead to models
with too many parameters, possibly causing multicol-
linearity and model instability. Although Bayesian mod-
eling of metabolic pathways with case-control data has
achieved some level of success (Conti et al. 2003), it is
difficult to evaluate whether complex models are ov-
erfitted to the data.
To improve power over that of standard methods, we
propose a class of nonparametric statistics that com-
bines information across all genetic markers, resulting
in a global statistic that has a standard normal distri-
bution. We expect that this approach would be sensitive
to situations in which multiple genes influence the dis-
ease but the effect of each individual gene is weak. Our
nonparametric methods are based on U-statistics, which
are used to measure an average genetic score between
pairs of subjects. Intuitively, we expect that any two
subjects with similar disease status should also have
similar genetic scores if any of the markers are associ-
ated with the disease. Hence, we measure the average
genetic score for all pairs of cases and compare this to
the average genetic score for all pairs of controls.
In the “Statistical Methods” section below, we de-
scribe the intuition and derivation of our methods,
showing their generality, as well as important special
cases. We illustrate how power can be computed, and
we use this to show how to determine an optimal ge-
notype score. To illustrate the properties of our meth-
ods, we perform simulations. We also apply our meth-
ods to a study of candidate genes for prostate cancer,
to illustrate their utility and interpretation.
Statistical Methods
To compare the distribution of all marker genotypes be-
tween cases and controls, we first compute the scores
for all possible pairs of subjects within each of the case
and control groups. We then contrast the average scores
between cases and controls by use of a global statistic
with one degree of freedom instead of the implicit many
degrees of freedom when many markers are analyzed.
U-Statistics for Within-Group Genotype Scores
First, consider a measure of genotype score within a
single group of n subjects. Let denote a vector ofgi
measured genotypes at K markers for subject i, with
element the kth genotype. To measure the score ofgi,k
all genotypes for subjects i and j, we use a symmetric
kernel, denoted as h( ). A general U-statistic thatg ,gi j
measures the average score across all pairs of subjects
is
h(g ,g )i j
!i jU p . (1)global n( )2
Hence, no matter how many markers are measured,
the global U-statistic uses a kernel function to reduce
the arrays of genetic markers for pairs of subjects into
a single score, which then are averaged across all possible
pairs. Although a wide variety of kernels can be consid-
ered, we shall consider primarily kernels that are additive
across all K markers, so that . Inh(g ,g )p  h(g ,g )i j i,k j,kk
general, the kernel can differ across markers, which
might be desirable if we knew that some markers are
likely to have dominant effects and others recessive ef-
fects. However, we assume that the same kernel is used
for all markers, to simplify our presentation. Additive
kernels are attractive because they make it easy to ac-
count for missing genotypes, weighted sums can be cre-
ated, and they can be computed rapidly. For example,
a weighted sum kernel in equation (1) results in
w h(g ,g )k i,k j,k
!i j kU pglobal n( )2
h(g ,g )i,k j,k
!i jp w k nk ( )2
p w U , k k
k
emphasizing that is a weighted sum of marker-Uglobal
specific U-statistics. Let denote the vector of marker-U
specific U-statistics. We shall contrast the vector be-U
tween cases and controls and average this contrast across
all markers. First, however, we need to consider the var-
iance matrix for the vector , because this variance ma-U
trix will be used to create optimal weights for averaging
across the markers.
We assume that subjects are independent of each other,
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but genetic markers can be correlated due to linkage
disequilibrium, or perhaps natural selection. To deter-
mine the asymptotic covariance matrix of , we useU
standard results on U-statistics (Hoeffding 1948, Serfling
1980). For now assume that there is no missing data.
Let , where lowercase g is fixedh (g )p E[h(g ,G )]1 i,k i,k j,k
and uppercase G is random. In other words, one of the
random genotypes is integrated out of the bivariate ker-
nel h to create the marginal function . Then, the as-h1
ymptotic covariances can be expressed as
 Cov ( nU , nU )p 4j , (2)k l k,l
where . To apply this generalj p Cov [h (G ),h (G )]k,l 1 i,k 1 i,l
expression, we need to account for missing data (i.e., to
allow n to vary over the different markers), and we need
a way to determine for a specified kernel.jk,l
We shall first illustrate the derivation of ,Var ( n U )k k
where denotes the number of subjects without missingnk
data for marker k. To determine , letj p Var [h (G )]k,k 1 i,k
denote the probability of genotype . The termP(g ) gk k
can then be expressed ash (g )1 i,k
h (g )p h(g ,G )P(G ) .1 i,k i,k k k
Gk
By using the genotype probabilities again, the expected
value of can be easily derived according toh (G )1 i,k
m p h (G )P(G ) (3)k 1 k k
Gk
and its variance according to
2 2j p h (G ) P(G ) m . (4)k,k 1 k k k
Gk
Then, .Var ( n U )p 4jk k k,k
Now consider . This covariance de- Cov ( n U , n U )k k l l
pends on the number of subjects that contribute to both
and ; let be this number. Then, allowing forU U nk l k,l
missing data,
4j n n nk,l k,l k l Cov ( n U , n U )p .k k l l (n n )k l
Note that this expression reduces to expression (2) when
there is no missing data (e.g., ). To deter-n p n p nk l k,l
mine , we reduce the sample to those subjectsj nk,l k,l
with complete data for both markers, and compute the
expected value of ,h (G )h (G )1 i,k 1 i,l
m p h (G )h (G )P(g ,g ) , (5)k,l 1 k 1 l k l
G Gk l
where is the joint probability of genotypes atP(g ,g )k l
both markers. This is then used to compute
j p m  m m . (6)k,l k,l k l
Computational Issues
The computations of the statistics and their co-Uk
variances are very time-consuming when summing over
all pairs of subjects. The most efficient computational
method is to weight the kernel scores by the counts of
distinguishable genotypes. Let denote the number ofxs
subjects with the sth genotype category ( ).sp 1, … ,S
Then, can be expressed asUk
h (g ,g )k i,k j,k
!i jU pk n( )2
S1 1xsp h(g ,g ) x x h(g ,g ) s s s t s t( )[ ]2n 2sp1 s(t( )2
S x (x  1)s sp h(g ,g ) s sn(n 1)sp1
x xs t2 h(g ,g ) . (7) s tn(n 1)!s t
The term in equation (7) is needed because the sum12
over gives a double count. Derivations of others( t
types of U-statistics for genetic studies have emphasized
this way of computing U-statistics (Kowalski 2001; Ko-
walski et al. 2002; Tzeng et al. 2003a, 2003b), and in
fact often rely on , where is the′Up P HPO(1/n) P
vector of relative frequencies of the categories (geno-
types, in our situation) and is a symmetric matrix ofH
corresponding kernel scores (Tzeng 2003).
To compute , we use the estimateVar ( n U )k k
to compute (eq. 3) and (eq. 4). ToˆP(g )p x /n m js s k k,k
compute , we subset to those subjects Cov ( n U , n U )k k l l
not missing data at both markers, create a contingency
table of genotype counts for , with cell countsg # gk l
, and use estimate in equationˆx P(g , g )p x /ng ,g k l g ,g k,lk l k l
(5) to compute .jk,l
Contrast of Case with Control Genotype Scores
To compare the vector of within-group scores for cases
with that for controls, we use the contrast vector
dp U U ,d c
where the subscripts d and c denote the diseased cases
and controls, respectively. Under the null hypothesis of
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Figure 1 Expected value of U-statistic, m, for the allele-match
kernel versus allele frequency (under the assumption of Hardy-Wein-
berg proportions of genotypes). For hypothetical allele frequencies, the
vertical solid lines represent cases and the vertical broken lines rep-
resent controls, illustrating that differences in expected kernels (delta)
between cases and controls can change sign according to whether allele
frequencies are less than or greater than 0.5.
no differences between cases and controls, standard re-
sults for U-statistics imply that has a multivariate nor-d
mal distribution with mean zero and covariance matrix
, which has elementsVo
4j 4jo,k,k o,k,k if kp l
n nd,k c,k
V p ,o,k,l
4j n 4j no,k,l d,k,l o,k,l c,k,l{  if k( l
n n n nd,k d,l c,k c,l
where is computed under the null hypothesis. Thisjo,k,l
is accomplished by pooling cases and controls to com-
pute estimates and and then using these toˆ ˆP(g ) P(g , g )s k l
estimate , as described above in the “Computationaljo,k,l
Issues” section.
To construct a statistic that is sensitive to alternatives
for which all elements of are in the same direction (i.e.,d
all positive or all negative), we use a weighted sum of
the elements of . To choose the weight vector , wed w
use the generalized least squares procedure, which pro-
vides the best (i.e., smallest variance) linear unbiased
estimator (BLUE) and corresponding optimal test sta-
tistic. In this case, the weight is proportional to thewk
kth row total of . That is,1Vo
′ 1 1 ′ 1w p (1 V 1) (1 V ) ,k o o k
where is a vector of ones. Hence, the global statistic1
is
′w d
Z p ,global ′w Vwo
and has an asymptotic standard normalZglobal
distribution.
Choice of Kernel for Genotype Scores
A challenging aspect of our proposed methods is the
choice of a kernel that is powerful for a wide range of
genetic effects. An intuitive choice is to simply count the
number of alleles that match between a pair of subjects;
we call this the “allele-match” kernel. This type of sim-
ilarity measure has been used for linkage statistics, such
as the affected-pedigree member linkage statistic (Weeks
and Lange 1988), and to evaluate the association of
haplotypes with disease (Tzeng et al. 2003b). This sim-
ilarity kernel counts the number of matches among the
four comparisons between the two alleles of subject i
and the two alleles of subject j, and it can be expressed
as
h(g p a /a ,g p a /a )i 1 2 j 3 4
p I[a p a ] I[a p a ]1 3 1 4
I[a p a ] I[a p a ] ,2 3 2 4
where is the indicator function having a value ofI[…]
1 or 0 according to whether its argument is true or false.
This kernel ranges from 0, for no matches, to 4, when
a pair of subjects have the same homozygous genotype.
On the surface, this similarity kernel is appealing, be-
cause one could easily extend it to multiple alleles and
multiple markers (summing the allele-match scores
across markers). However, further consideration shows
that it can have undesirable properties when summing
across markers and contrasting between cases and con-
trols. The main issue is that the expected value of this
allele-match kernel is symmetric about its minimum
value, which occurs when all alleles at a marker have
the same frequency. For example, consider a diallelic
marker, with one of the alleles having frequency p. Under
the assumption of Hardy Weinberg proportions for the
genotypes, the expected value of the allele-match kernel
is . This expectation is illus-m p 4 8p(1 p)allele match
trated in figure 1, which shows that it is symmetric
around 0.5. In this figure, we also plot solid vertical lines
for cases and broken vertical lines for controls, for hy-
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Table 1
Examples of Kernels for
Genotypes andg gi j
gi
gj
a/a a/b b/b
Allele Match
a/a 4 2 0
a/b 2 2 2
b/b 0 2 4
Linear Dosage
a/a 0 1 2
a/b 1 2 3
b/b 2 3 4
Dominant
a/a 0 1 1
a/b 1 2 2
b/b 1 2 2
Recessive
a/a 0 0 1
a/b 0 0 1
b/b 1 1 2
Quadratic
a/a 2 3 5
a/b 3 4 6
b/b 5 6 8
Table 2
Contingency Table for Computing
Armitage’s Test for Trend
a/a a/b b/b Total
Cases r0 r1 r2 R
Controls s0 s1 s2 S
Total n0 n1 n2 N
pothetical allele frequencies such that cases have higher
allele frequencies than controls. These vertical lines il-
lustrate that when allele frequencies are !0.5, the dif-
ference in the mean scores between cases and controls
(“delta” in fig. 1) will be negative. In contrast, when
allele frequencies are 10.5, the delta will be positive.
Summing over these two hypothetical markers is equiv-
alent to summing over deltas of opposite signs and hence
eliminates any potential signal for the association. It can
be shown that a similar problem exists when there are
more than two alleles at a marker, with the expected
kernel score having its minimum value when alleles are
equally frequent. That is, similarity is smallest when ge-
notypes have the greatest amount of variability, which
occurs when alleles are equally frequent. Hence, com-
paring average similarities between cases and controls
will be influenced by how much the allele frequencies
depart from equality within a group, potentially elimi-
nating a signal when summing these allele-match kernels
across markers.
Because of the problems with the allele-match ker-
nel, we consider an alternative approach. One can score
each subject’s genotype separately, by a dosage function
, and then sum these dosage functions for a pair ofd(g)
subjects to create a kernel, . Forh(g ,g )p d(g ) d(g )i j i j
example, for diallelic markers, one can count the number
of alleles of a specific type, such as the more rare allele,
to create the linear dosage score . This “lin-d(g)p 0,1,2
ear-dosage” kernel, along with the above allele-match
kernel, and a few other kernels based on the sum of
other dosage functions, are illustrated in table 1. Before
we describe how to determine an optimal kernel for a
specified genetic effect, we show in the next section that
the “sum-dosage” kernel, , withh(g ,g )p d(g ) d(g )i j i j
an arbitrary dosage score , leads to a U-statistic thatd(g)
is equivalent to Armitage’s trend statistic for propor-
tions. This relationship provides an intuitive guide on
the choice of kernels.
Relationship of Contrast of Within-Group U-Statistics
with Armitage’s Test for Trend.—Armitage’s test for trend
in proportions is frequently used to compare the geno-
type frequencies between cases and controls. For diallelic
markers, the 2# 3 table for affection status by genotype
category can be arranged as in table 2. Armitage’s trend
statistic measures a trend in proportions, weighted by a
general measure of exposure dosage, . Armitage’s trenddi
statistic can be expressed as , whereZ p T/ Var (T)Arm
S R
Tp d r  s , i i i( )N Ni
2 2Nd n  d ni i i i( )
i i
Var (T)p RS ,3N
and summations are over all possible genotypes. The
statistic has an approximate standard normalZArm
distribution.
A common way to score the genotypes is to let
, according to the count of the number of rared p 0,1,2i
b alleles. For this type of scoring, reduces to Pear-2ZArm
son’s x2 statistic for the 2# 2 table that compares allele
counts between cases and controls when the genotypes
are in Hardy-Weinberg proportions (Devlin and Roeder
1999), yet the statistic is robust to departures fromZArm
Hardy-Weinberg proportions (Sasieni 1997). Further-
more, is the score statistic from logistic regression,2ZArm
when the independent covariate for the genotypes is
coded as 0, 1, or 2 for the number of copies of allele b.
The power of Armitage’s statistic depends on how close
the chosen scoring of genotypes matches the true genetic
effect (Slager and Schaid 2001). For example, if allele b
is dominant, then the most powerful scoring is dp
for genotypes , , and . For a recessive0,1,1 a/a a/b b/b
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Table 3
Relative Efficiency of Different Kernels for Different Genetic
Effects
MODEL, w,
AND P
RELATIVE EFFICIENCY FOR KERNELa
Dominant Recessive
Linear
Dosage Quadratic
Dominant:
w p 2:
.05 1 .15 .99 .95
.25 1 .27 .91 .79
w p 4:
.05 1 .14 .99 .95
.25 1 .25 .9 .76
Recessive:
w p 2:
.05 .19 1 .37 .52
.25 .35 1 .7 .85
w p 4:
.05 .24 1 .46 .62
.25 .41 1 .77 .89
Multiplicative:
w p 2:
.05 .99 .35 1 .98
.25 .91 .69 1 .96
w p 4:
.05 1 .4 1 .95
.25 .89 .76 1 .96
a Relative efficiency is the ratio of noncentrality parameters,
where a noncentrality parameter for a specified kernel is .d/j
effect of allele b, the corresponding scoring should be
. For an additive effect on the log odds ratio,dp 0,0,1
the most powerful scoring is linear, .d p 0,1,2i
When there are only two alleles at a marker, it can be
shown that Armitage’s trend test is a special case of our
d contrast statistic that contrasts the within-group U-
statistic for cases with that for controls when a particular
kernel is used. Let denote the dosage scoring ofd(g )i
genotype for Armitage’s trend test. Then, if the kernelgi
is defined to be the sum of these genotype dosage scores,
, it can be shown that the numer-h(g ,g )p d(g ) d(g )i j i j
ator of Armitage’s trend test, T, and havedp U Ud c
the relationship , where . Further-Tp dC Cp RS/(2N)
more, , so that the standardized sta-2Var (T)p Var (d)C
tistics are equivalent. This equivalence allows us to de-
termine the most powerful kernels for the U-statistics,
by first choosing for a specified genetic effect andd(g)
then converting this to a sum kernel.
Kernels that Maximize Power.—Power depends on the
choice of kernel, as well as the distribution of genotypes
for cases and controls. Let , , and denote theQ Q Q0 1 2
genotype probabilities for the controls having genotypes
, , and , respectively. Let , , and denotea/a a/b b/b P P P0 1 2
the corresponding genotype probabilities for the cases.
These probabilities correspond to the layout of table 2.
The probabilities for the cases can be expressed in terms
of odds ratios and the genotype probabilities for the
controls. Let and denote the odds ratios for ge-w w1 2
notypes and , relative to genotype . Then,a/b b/b a/a
w Q1 1P p ,1 Q  w Q  w Q0 1 1 2 2
w Q2 2P p ,2 Q  w Q  w Q0 1 1 2 2
and, of course, . When the appropriateP p 1 P  P0 1 2
genotype probabilities are used, the expected value of d
is , where m is the expected value of the U-statistic,m  md c
as illustrated in equation (3), evaluated with either the
case or control genotype probabilities. The variance
term, , is computed according to equation (4). Because2j
the variance term is computed under the null hypothesis
by pooling cases and controls, we use the average of the
genotype probabilities for cases and controls (e.g.,
for equal numbers of cases and controls) in[PQ]/2
the variance formula. Under the assumption that the
number of cases, n, is equal to the number of controls,
the power for a one-sided test ( ) is , whered 1 0 1 F(z )b
F is the cumulative distribution function for a standard
normal distribution,
dz p z  n ,b a 28j
and is the quantile of the standard normalz (1 a)a
distribution. It is clear from the above expression that
power is maximized by maximizing . For a given dis-d/j
tribution of genotypes for controls and specified geno-
type odds ratios, the goal is to determine which values
of the kernel maximize . We accomplish this by usingd/j
the simplex method (Press et al. 1992). This method is
used to find parameters that minimize a general function;
in our case, we minimize . Because multiple so-2(d/j)
lutions give the same minimum and, hence, the same
power, we restricted the kernels to be nondecreasing as
genotype similarity increases. That is, for kernels dis-
played as in table 1, we require that the elements within
a row do not decrease as we read from left to right, and
elements within a column do not decrease as we read
from top to bottom. We applied this approach to a va-
riety of genetic models, including rare and common al-
leles (i.e., those with disease allele frequencies equal to
0.05 or 0.25, respectively), and dominant, recessive, or
multiplicative effects of the disease allele. These effects
were modeled by the odds ratios, with dominant having
, recessive having , and mul-w p w p w w p 1, w p w1 2 1 2
tiplicative having , with , and w having2w p w w p w2 1 1
a value of either 2 or 4. In all cases, we could not find
kernels with greater power than those predicted by the
corresponding “sum” kernels, as outlined in the previous
section.
To illustrate the relative efficiency of the different sum
kernels for different genetic models, we present in table
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Figure 2 Standardized for the allele-match and linear-dosaged/j
kernels, under the assumption that the allele frequency for controls is
, where is the allele frequency for cases (X-axis).p  0.05 pd d
3 the relative efficiencies of a variety of kernels. The
kernels “dominant,” “recessive,” and “linear” are based
on the dosage functions defined in the previous sec-d(g)
tion. The “quadratic” kernel is based on .d(g)p 1,2,4
The relative efficiencies in table 3 are presented such that
the kernel with greatest power has a value of 1. The
interpretation of a less-efficient kernel is that the sample
size would need to be increased by , where e is the1/e
relative efficiency in table 3. The results in table 3 illus-
trate that when a recessive kernel is used for a dominant
effect, there is a large loss in efficiency, and vice versa.
The linear kernel performs best for multiplicative models
(i.e., log-additive effects) and performs well for domi-
nant effects but poorly for recessive effects. Although
the quadratic kernel is not the most efficient for any of
the presented models, it is fairly robust, performing rea-
sonably well for most genetic models, except for rare
recessive effects. This suggests that the quadratic kernel
may be a reasonable choice when the true underlying
genetic effect is unknown—a frequent situation.
Although not immediately obvious, the allele-match
kernel and the linear-dosage kernel give the same statistic
for a diallelic marker, except that the sign of the statistics
can differ, depending on the allele frequencies for cases
and controls. This follows from the symmetry in figure
1 for the allele-match kernel, whereas the linear-dosage
kernel has expected value , which is am p 4plinear dosage
straight line with slope 4, and so avoids the complica-
tions when adding contrasts between cases and controls
across markers. Without showing all the detailed alge-
braic derivations, it can be shown that the ratio of d/j
for the allele-match kernel over that for the linear-dosage
kernel is equal to 1 if and is equal to 1(p  p) ! 1d c
if , where and are the frequencies of one(p  p) 1 1 p pd c d c
of the alleles for the cases and controls. In figure 2, we
plot for both kernels, for . This illus-d/j p p p  0.05c d
trates that the absolute magnitudes of the statistics are
equal, yet different in sign, when the allele frequencies
for cases and controls are both !0.5. This again em-
phasizes caution when the allele-match kernel is being
used for multiple markers.
Simulations
A series of simulations were used to evaluate the type I
error rates and the power of our proposed statistic,Zglobal
relative to the power of the maximum of the single-
marker tests with Bonferroni correction for multiple test-
ing (denoted as “max-single”), and the power of Ho-
telling’s multimarker multivariate statistic (denoted2T
as “multimarker”). The genotypes for 10 independent
markers were simulated, and, of these 10, the number
of markers associated with disease ranged from 0 (to
evaluate the type I error rate) to 10. The frequency of
the high-risk allele, for all markers, was set to either
0.05 or 0.10 (denoted in our tables as “MAF,” for “mi-
nor allele frequency”). Hardy-Weinberg proportions
were used to generate the genotypes for the controls,
and the genotypes for cases were generated by assuming
that the high-risk allele had a multiplicative effect on
the odds ratio. The effect per allele was set at either 1.25
or 1.5. The total sample size was set to either 500 or
1,000 individuals, of which half were cases and half were
controls. Two-sided tests were used, and all simulations
were based on 1,000 replicates.
The type I error rates for all three of the test statistics,
calculated using a variety of kernels for , are pre-Zglobal
sented in table 4. Almost all type I error rates for
and multimarker are within the 95% CIs for theZglobal
nominal error rates ( , 95% CI 0.004–0.016;ap 0.01
, 95% CI 0.036–0.064), suggesting that theap 0.05
normal distribution is adequate for the null distribution
of and that the x2 distribution is adequate forZglobal
multimarker. For the max-single statistic, the type I er-
ror rates are also adequate, except for the recessive ker-
nel, which was overly conservative (most likely because
of the sparseness of homozygotes for the more rare
allele).
The power of the linear kernel for , the max-Zglobal
single statistic, and the multimarker statistic, with a type
I error rate of 0.05, are presented in figure 3 for high-
risk allele frequencies of 0.05 and in figure 4 for high-
risk allele frequencies of 0.10. The X-axis presents the
number of high-risk markers, ranging from 0 to 10.
These figures illustrate that, as the number of high-risk
markers increases, there is a gain in power of the
statistic over the max-single and multimarker sta-Zglobal
tistics, and that the gain is greatest when the effect size
of the high-risk allele is not large (odds ratio per allele
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Table 4
Type I Error Rates for max-single, multimarker, and
StatisticsZglobal
a, KERNEL, MAF,
AND N
TYPE I ERROR RATE FOR
max-single multimarker Zglobal
a p .01:
Linear dosage:
MAF p .05:
500 .005 .007 .008
N p 1,000 .009 .008 .01
MAF p .10:
N p 500 .011 .01 .009
N p 1,000 .013 .013 .01
Quadratic:
MAF p .05:
N p 500 .002 .008 .021
N p 1,000 .01 .011 .018
MAF p .10:
N p 500 .009 .009 .014
N p 1,000 .003 .009 .008
Dominant:
MAF p .05:
N p 500 .005 .007 .009
N p 1,000 .009 .01 .012
MAF p .10:
N p 500 .009 .008 .018
N p 1,000 .006 .008 .008
Recessive:
MAF p .05:
N p 500 0 .009 .005
N p 1,000 0 .011 .006
MAF p .10:
N p 500 0 .005 .003
N p 1,000 0 .012 .007
a p .05:
Linear:
MAF p .05:
N p 500 .034 .042 .041
N p 1,000 .051 .057 .055
MAF p .10:
N p 500 .056 .058 .042
N p 1,000 .053 .061 .06
Quadratic:
MAF p .05:
N p 500 .05 .055 .048
N p 1,000 .047 .046 .047
MAF p .10:
N p 500 .041 .039 .055
N p 1,000 .054 .05 .061
Dominant:
MAF p .05:
N p 500 .053 .054 .048
N p 1,000 .038 .047 .038
MAF p .10:
N p 500 .048 .038 .06
N p 1,000 .047 .043 .046
Recessive:
MAF p .05:
N p 500 0 .056 .034
N p 1,000 0 .046 .031
MAF p .10:
N p 500 0 .042 .056
N p 1,000 .017 .051 .062
of 1.25 in the figures). The benefit of using the Zglobal
statistic seemed to occur when there were 13 high-risk
markers among the set of 10 markers in these simula-
tions. In contrast, when there were only one or two
high-risk markers, the max-single and multimarker sta-
tistics had greater power than the statistic. ThisZglobal
was most accentuated when both the allele effect size
and the sample size were large (see lower right panel of
fig. 4).
Although our simulation results show the potential
gain in power provided by the statistic, our sim-Zglobal
ulations are somewhat unrealistic, assuming no inter-
actions among the high-risk markers. Simulating true
biological mechanisms is also unrealistic, given our lim-
ited knowledge of underlying genes influencing complex
disease. So, to evaluate how our methods behave in the
presence of interactions, we consider two extreme sce-
narios. For the 10 markers, there are 45 possible pair-
wise interactions. In the first scenario, we simulate from
a logistic model that has no main effects, but all 45
pairwise interactions contribute to the logistic regres-
sion model according to , where and are thex x b x xk l l l
linear dosage scores for the rare alleles at markers k
and l, and b is the log odds ratio for the interaction
effect; we allow the interaction odds ratio to be either
1.1. or 1.25. In the second scenario, we also assume no
main effects, but 22 of the interactions have positive
values of b and 23 have negative ones. That is, half the
interactions increase disease risk, and the other half de-
crease disease risk. The results from these simulations
are presented in table 5. When all interactions are pos-
itive, the statistic has a substantial power advan-Zglobal
tage over the other methods. This is likely because all
methods are picking up some signal from the main ef-
fects of each marker (main effects and pairwise inter-
actions are correlated), but the signal of each main effect
is weak, so the weighted average over all markers
strengthens the signal. In contrast, the model with half-
positive and half-negative interactions creates main ef-
fects that have opposite signs, so that the weighted av-
erage for is near zero. Note that max-single andZglobal
multimarker also have weak power for this interaction
model.
Application to Prostate Cancer Candidate Genes
To evaluate common genetic polymorphisms for genes
that are likely to be associated with prostate cancer, we
measured common variations of single nucleotide poly-
morphisms (SNPs), chosen such that the minor allele
frequency was expected to be at least 5%, in order to
have adequate power to detect moderate associations.
A total of 499 cases and 493 controls were recruited.
We have focused on two biologic pathways: (1) 17 SNPs
for genes that encode enzymes in the androgen metabolic
pathway and (2) 17 SNPs for genes that encode enzymes
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Figure 3 Power from simulated data with the number of high-risk markers ranging from 0 to 10 among 10 markers, with a minor allele
frequency of 0.05 for each marker.
involved in the estrogen metabolic pathway (authors’
unpublished data). These two pathways are presented
in figure 5. The 34 SNPs are identified by numbers within
boxes, with their corresponding gene labels. Note that
some genes have multiple SNPs measured; these were at
different sites within the gene, at positions where prior
reports suggested that variants might be associated with
the risk of prostate cancer. This figure also illustrates
that these two pathways have some biological links, al-
though we analyze them separately.
The association of all SNPs within a pathway with
prostate cancer status was evaluated with the global
statistic , using different types of kernels. The re-Zglobal
sults of these global tests are presented in table 6. No
tests for the androgen pathway SNPs showed statisti-
cally significant associations. For the estrogen pathway
SNPs, the quadratic kernel resulted in a statistically sig-
nificant association ( ), and the linear kernelPp .028
was marginally significant ( ).Pp .074
Although our proposed methods control the overall
type I error rate, interpretation of a significant global
test can be difficult. To evaluate which markers “ex-
plain” the significance of the global test, we performed
a stepwise procedure. Intuitively, we expect that re-
moval of the markers that explain the statistical signif-
icance of the global test should result in nonsignificance
of the remaining markers. However, because the statis-
tical tests can be correlated, we account for this by con-
ditioning on the removed markers when evaluating the
markers that are kept. Furthermore, because the global
statistic is computed under the null hypothesis, all com-
putations of the stepwise adjusted statistics are also
computed under the null hypothesis, to evaluate which
markers are the most influential. To start, the marker
with the smallest single-marker P value is removed, and
a global test for the remaining markers is performed,
adjusted for the removed marker. To determine the next
marker to remove, we create a test statistic for each of
the kept markers, with each statistic adjusted for the
set of removed markers, and then remove the marker
that has the smallest P value. After a marker is removed,
a global test is performed for the kept markers, adjusted
for all of the removed markers. This process is continued
until the global adjusted test is no longer significant. To
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Table 5
Simulated Power for Pairwise Interaction Models
MODEL, MAF,
AND ODDS
RATIO
SIMULATED POWER FOR
max-single multimarker Zglobal
All positive:
MAF p .05:
1.1 .054 .022 .104
1.25 .104 .050 .522
MAF p .10:
1.1 .135 .73 .503
1.25 .614 .595 .998
Half positive:
MAF p .05:
1.1 .044 .014 .049
1.25 .070 .027 .060
MAF p .10:
1.1 .077 .045 .052
1.25 .265 .194 .062
Figure 4 Power from simulated data with the number of high-risk markers ranging from 0 to 10 among 10 markers, with a minor allele
frequency of 0.10 for each marker.
illustrate this adjustment procedure, partition the d vec-
tor into the markers kept and removed, ,dp (d ,d )k r
where the subscripts k and r denote “kept” and “re-
moved,” respectively. Partition the null variance matrix
accordingly, into submatrices , , and . FromV V Vk,k k,r r,r
multivariate normal theory, under the null hypothesis,
the distribution of conditional on is multivariated dk r
normal with mean vector
1m p V V dk.r k,r r,r r
and variance matrix
1 ′V p V V V V .k.r k,k k,r r,r k,r
We use the adjusted covariance matrix to define theVk.r
weight vector , to compute the global statistic forwk.r
the kept markers, adjusted for all the removed markers,
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Table 6
Global Tests of Association of All SNPs within a Pathway with
Prostate Cancer Status
PATHWAY
GLOBAL P FOR KERNEL
Linear Dosage Quadratic Dominant Recessive
Androgen .590 .706 .395 .958
Estrogen .074 .028 .281 .654
Figure 5 Candidate genes that are involved with the metabolism of androgen and estrogen. The androgen portion of the pathway is
within the broken line, and the estrogen pathway is outside of the broken line, at the bottom of the figure. The measured SNPs are indicated
within boxes, with their corresponding genes labeled and the SNPs numbered below each gene. Other genes and enzymes that are part of the
pathway are also illustrated, emphasizing that the measured SNPs are for genes whose products act at different steps of androgen and estrogen
biosynthesis.
′w (d  m )k.r k k.rZ p .global adjusted ′w V wk.r k.r k.r
To determine the next marker to remove, adjusted for
all markers removed at prior steps, we use the statistic
for the ith single marker, adjusted for the previously
removed markers,
(d  m )k,i k.r,iZ p .i Vk.r,i,i
Both the single-marker–adjusted and global-adjus-
ted statistics have an asymptotic standard normal
distribution.
The results from the first three steps of removing “ex-
planatory” SNPs are presented in table 7, for the linear
and quadratic kernels. The global statistics are adjusted
for the all the previously removed SNPs. For compar-
ison, we also present the marginal single-marker P val-
ues, not adjusted for other SNPs and not adjusted for
multiple testing. The Bonferroni correction would re-
quire the marginal single-marker P values to be !0.0029
to achieve statistical significance, which none of our
SNPs achieved. In contrast, the global test for the quad-
ratic kernel, at step 0, demonstrates statistical signifi-
cance, emphasizing the benefit of our global test. On
the basis of the quadratic kernel, it appears that the
SNPs HSD17B1 and NQ01 have the most influence on
the global test, since conditioning on these two SNPs,
the global test has a P value of 0.111; the SNP CYP1A1
may also have some influence, although the statistical
evidence is weaker. Similar evidence, although not as
dramatic, is provided by the linear kernel.
Discussion
Common diseases are expected to be controlled by com-
plex genetic mechanisms, with small-to-moderate effect
sizes per gene, because of natural selection having re-
moved those genes with large effects. Given the large
body of evidence indicating that metabolic pathways are
likely to play a major role in complex diseases and that
these types of pathways have complex interactions and
feedback loops, it would not be surprising to find that
multiple genes within a biologic pathway are associated
with disease, complicated by both allelic and locus het-
erogeneity. Recognizing that testing the association of
disease with one marker at a time can have weak power
due to small genetic effects and the need to correct for
multiple testing, we have proposed a class of U-statistics
that combine information from multiple genetic mark-
ers. This combined statistic achieves its greatest power
when the contrasts of the within-group genetic scores
between cases and controls are in the same direction
across multiple markers.
The multimarker Hotelling’s statistic is limiting,2T
because it does not allow for missing genotypes at some
markers and does not combine information across
markers into a single-df statistic, which would have less
power than our proposed methods when the effects of
genotypes are in the same direction across markers.
Hence, an advantage of our approach is that it provides
a mechanism to handle missing data while combining
results from multiple markers.
Another advantage of our methods is the general
framework to consider alternative types of kernels. The
allele-match kernel has intuitive appeal but can be lim-
iting, because it is influenced by how much allele fre-
quencies differ from equality within a group—which,
in turn, can cause contrasts between cases and controls
to differ in sign across markers. Further work is needed
to evaluate the best kernels when there are multiple
alleles per marker. To provide guidance on the choice
of kernel, we have illustrated how to compute the power
for a given type of kernel and a specified genetic effect
size (e.g., in terms of control genotype frequencies and
genotype odds ratios). Our numerical comparisons sug-
gest that the quadratic kernel is fairly robust, in the
sense that it does not lose as much power as other ker-
nels, despite not giving the greatest power.
All of our proposed kernels are additive across mark-
ers. The benefit of an additive kernel is that it can easily
handle missing marker data, which is a common oc-
currence. Furthermore, weighted averages can be easily
computed, where the weights are data driven, with the
optimal weights determined by BLUEs. This strategy has
been used elsewhere in genetics, such as in the use of
792 Am. J. Hum. Genet. 76:780–793, 2005
Table 7
Global Tests Adjusted for SNPs Removed Sequentially, as well as
Marginal P Values for Single-Marker Tests (Not Adjusted for
Multiple Testing)
STEP
SNP
REMOVED
P VALUE
Global Single Marker
Linear
Dosage Quadratic
Linear
Dosage Quadratic
0 None .074 .028
1 HSD17B1 (20) .143 .053 .018 .034
2 NQ01 (31) .252 .111 .048 .049
3 CYP1A1 (21) .510 .339 .140 .123
generalized least squares to derive BLUEs of allele fre-
quencies from pedigree data (McPeek et al. 2004).
Weighted global statistics have been also used to derive
optimal nonparametric statistics to compare two treat-
ment groups over multiple endpoints (O’Brien 1984;
Wei and Johnson 1985). Further work is warranted to
determine if more powerful kernels can be found, such
as kernels that are nonlinear over the genetic markers.
For example, kernels that increase exponentially with
the number of rare variants across multiple markers
might be more sensitive to situations in which multiple
rare variants are required for disease, suggesting higher-
order interactions among markers.
A potential advantage of our approach is that linkage
disequilibrium among markers is implicitly accounted
for by the covariance matrix of the vectors. ThisU
allows our methods to be used in evaluating the asso-
ciation of multiple markers within a candidate gene with
disease. A potential limitation is that we do not evaluate
the association of haplotypes (i.e., particular combi-
nations of alleles on a chromosome) with disease, as
others have proposed (Tzeng et al. 2003b). However,
carefully selected SNPs that “tag” a haplotype can re-
duce the number of SNPs that are required to be ge-
notyped, and analyzing these types of markers jointly—
yet without regard to haplotype phase—can increase the
power over haplotype analyses, because of the reduced
degrees of freedom for joint marker analyses relative to
the many degrees of freedom for haplotype analyses
(Chapman et al. 2003). If all contrasts of marker scores
between cases and controls are in the same direction,
then our global statistic with 1 df will have even greater
power, as is demonstrated by our simulations.
Our simulations suggest that the global statistic main-
tains the appropriate type I error rate and that the power
of the global statistic is greater than both single-marker
and multimarker tests when there are more than just a
few associated genetic markers. Application to our pros-
tate cancer study illustrates the potential gain of our
global test by providing significant results that would
not be found significant by use of single-marker tests
with Bonferroni correction. However, this example also
illustrates that, once found, a significant global test can
be difficult to interpret, because it is not immediately
clear which markers are driving the statistical signifi-
cance. To guide our interpretation, we used a stepwise
removal of the markers that had the smallest single-
marker P value, with recomputation of an adjusted
global test after each marker was removed. This process
helped to identify a few markers that seemed to con-
tribute the most to the global test. Further work re-
garding the statistical properties of the proposed step-
wise procedure might be beneficial, since many stepwise
selection procedures are known to have some difficul-
ties identifying the most important subsets. Cross val-
idation, to determine the ability to replicate the most
important subset of explanatory markers, may offer
guidance.
In summary, we have proposed a novel class of U-
statistics that provide a simultaneous test of association
of multiple genetic markers with disease. Our approach
is quite general, allowing a wide variety of kernels to
be used. Simulations demonstrate that our approach
can be more powerful than standard methods, and
application to our prostate cancer study illustrates
the potential merits of our statistics, as well as their
interpretations.
Software
Software that implements the methods described in this
manuscript is written in the S programming language as
a package called multigene, which runs in both S-PLUS
and R computing environments. The package will be
available from our Web site (http://mayoresearch.mayo
.edu/mayo/research/biostat/schaid.cfm) and, for R users,
from the Comprehensive R Archive Network site (http:
//cran.us.r-project.org).
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